Revelation Biosciences (NASDAQ:REVB) Trading Down 1.9% – Here’s Why

Revelation Biosciences, Inc. (NASDAQ:REVB)’s share price fell 1.9% during mid-day trading on Wednesday . The company traded as low as $1.02 and last traded at $1.03. Approximately 17,868 shares were traded during trading, a decline of 62% from the average daily volume of 47,198 shares. The stock had previously closed at $1.05.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research report on Thursday, June 18th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Revelation Biosciences presently has a consensus rating of “Sell”.

Revelation Biosciences Trading Down 1.9%

The business has a fifty day simple moving average of $1.07 and a two-hundred day simple moving average of $1.85. The stock has a market cap of $4.03 million, a PE ratio of -0.03 and a beta of -0.09.

Revelation Biosciences (NASDAQ:REVB) last announced its earnings results on Thursday, May 7th. The company reported ($2.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($1.56). On average, research analysts predict that Revelation Biosciences, Inc. will post -4.99 earnings per share for the current year.

Institutional Trading of Revelation Biosciences

A number of hedge funds have recently modified their holdings of the business. Armistice Capital LLC grew its position in shares of Revelation Biosciences by 442.8% in the 4th quarter. Armistice Capital LLC now owns 434,272 shares of the company’s stock worth $347,000 after buying an additional 354,272 shares during the period. Sabby Management LLC boosted its stake in Revelation Biosciences by 192.5% during the fourth quarter. Sabby Management LLC now owns 605,702 shares of the company’s stock worth $484,000 after acquiring an additional 398,651 shares in the last quarter. Finally, Geode Capital Management LLC bought a new stake in Revelation Biosciences during the fourth quarter worth about $27,000. Institutional investors own 12.80% of the company’s stock.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.